The Pharma Data

DECEMBER 7, 2020

But studies exploring its impact on them remain scant, an analysis of clinical trials over the past decade shows. based clinical trials investigating interventions for high blood pressure between 2009-2018, just 52 were exclusively in Black people. This impedes our ability to develop new and novel interventions and treatments.”

Treatment 52

Treatment Clinical Trials Trials Doctors 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. What will have the greatest impact on rare disease patients in 2023?

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Target Review

JUNE 29, 2023

Success in the haematology space has really been driving this from the beginning, which is not surprising as haem doctors understand stem cell transplants; they’re used to working with a lot of the sort of toxicities that can come with cell therapies. When it comes down to cell biology itself, cells can do so many different things.

Therapies 115

Therapies Science Production Cell Biology 115

Codon

JULY 21, 2024

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” Another part of providing research animals with a good life is granting them a good death.

Research 113

Research Engineering Science Disease 113

Drug & Device Law

DECEMBER 4, 2023

Abuse of substantive law as a weapon to force settlement occurs so frequently in multidistrict litigation (“MDL”), that we’ve given it a name – “the MDL treatment.” The linchpin of the MDL treatment is that plaintiffs are allowed to take way more liberties with state law than the Erie doctrine allows. 662, 679 (2009).

Production 52

Production Trials Treatment Pharmaceuticals 52

Drug & Device Law

JULY 24, 2023

Yet what the plaintiffs were claiming is that, despite Actos’ undisputed effectiveness as a diabetes treatment, no TPP in the country would have purchased it for that purpose because of the 3/10,000 bladder cancer increased risk. at *6 (plaintiff “has documents and formularies reaching back to only 2009”). PATDC82 I , 943 F.3d

Testimonials 52

Testimonials Pharmacy FDA Doctors 52

Drug & Device Law

JUNE 6, 2022

Thus a confident learned intermediary’s testimony will defeat causation as a matter of law by stating that, notwithstanding a poor result, the treatment provided was standard of care, and even in hindsight they would not do anything different. 2009), reversed a plaintiff’s verdict for entry of judgment n.o.v. caused anything.

Testimonials 59

Testimonials Production Pharmaceuticals Treatment 59